Stay updated on Nivolumab + HF10 for Resectable Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page.

Latest updates to the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov site revision in the footer changed from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check8 days agoChange DetectedThe ClinicalTrials.gov record for the neoadjuvant nivolumab and HF10 melanoma trial is displayed with its study details, eligibility criteria, outcomes, and results. It identifies the trial as terminated and no longer recruiting participants.SummaryDifference46%

- Check15 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0 while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check29 days agoChange DetectedA banner announces NIH website updates and a terminology transition from “Artificial Intelligence” to “Super Intelligence.” The site revision number changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check43 days agoChange DetectedThe footer revision number advances from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check57 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study details, replacing the content with a basic header/footer and preventing access to the study record.SummaryDifference18%

Stay in the know with updates to Nivolumab + HF10 for Resectable Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page.